Delphinus Medical Technologies develops and services solutions to prevent breast cancer through screening and imaging.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/20/2023 | Series E | $5MM | $xx.xx | $208.48MM | Trinity Capital Inc. | |
Price per Share
$xx.xx
Shares Outstanding
3,440,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Trinity Capital Inc.
|
||||||
09/29/2022 | Series D-1 | $1.5MM | $xx.xx | $250.12MM | Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures, Waycross Ventures | |
Price per Share
$xx.xx
Shares Outstanding
1,735,910
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures, Waycross Ventures
|
||||||
09/29/2022 | Series D | $28.91MM | $xx.xx | $250.12MM | Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures, Waycross Ventures | |
Price per Share
$xx.xx
Shares Outstanding
24,978,505
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures, Waycross Ventures
|
||||||
04/13/2017 | Series C-2 | $64.68MM | $xx.xx | $134.29MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
109,504,429
Liquidation Pref Order
3
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|
||||||
04/13/2017 | Series C-1 | $720,134 | $xx.xx | $134.29MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,201,346
Liquidation Pref Order
4
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|
||||||
09/10/2015 | Series C | $40.27MM | $xx.xx | $59.47MM | Hopen Life Science Ventures, Waycross Ventures, Arboretum Ventures, Beringea, North Coast Technology Investors | |
Price per Share
$xx.xx
Shares Outstanding
68,175,922
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Hopen Life Science Ventures, Waycross Ventures, Arboretum Ventures, Beringea, North Coast Technology Investors
|
||||||
09/12/2013 | Series B | $7.86MM | $xx.xx | $26.78MM | Arboretum Ventures, Beringea, North Coast Technology Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,856,727
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Arboretum Ventures, Beringea, North Coast Technology Investors
|
||||||
05/14/2010 | Series A | $9.55MM | $xx.xx | $14.69MM | Beringea, Arboretum Ventures, Wolverine Venture Fund, North Coast Technology Investors, InvestMichigan | |
Price per Share
$xx.xx
Shares Outstanding
9,550,000
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.5x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Beringea, Arboretum Ventures, Wolverine Venture Fund, North Coast Technology Investors, InvestMichigan
|